Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Neuren Pharmaceuticals Limited ( (AU:NEU) ) just unveiled an update.
Neuren Pharmaceuticals Limited has announced an update regarding its ongoing on-market buy-back program. As of May 7, 2025, the company reported the buy-back of 36,134 ordinary fully paid securities on the previous day, contributing to a total of 2,958,937 securities bought back to date. This buy-back initiative is part of Neuren’s strategy to optimize its capital structure and potentially enhance shareholder value.
More about Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited operates in the pharmaceutical industry, focusing on the development of therapies for neurodevelopmental and neurodegenerative disorders. The company is known for its commitment to advancing treatments that address significant unmet medical needs.
Average Trading Volume: 703,479
Technical Sentiment Signal: Hold
Current Market Cap: A$1.59B
Learn more about NEU stock on TipRanks’ Stock Analysis page.